Media headlines about NewLink Genetics Corporation (NASDAQ:NLNK) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. NewLink Genetics Corporation earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.413834945184 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
Several research analysts have recently commented on the company. ValuEngine downgraded NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Cantor Fitzgerald reiterated a “buy” rating and set a $26.00 target price on shares of NewLink Genetics Corporation in a research report on Monday, September 25th. Zacks Investment Research cut NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Stifel Nicolaus increased their target price on NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Finally, Robert W. Baird upgraded NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $8.00 to $22.00 in a research report on Friday, September 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. NewLink Genetics Corporation currently has a consensus rating of “Buy” and an average target price of $25.83.
NewLink Genetics Corporation (NLNK) opened at 9.52 on Friday. The firm’s 50-day moving average price is $11.27 and its 200 day moving average price is $10.78. The stock’s market cap is $280.09 million. NewLink Genetics Corporation has a 12-month low of $5.90 and a 12-month high of $25.17.
NewLink Genetics Corporation (NASDAQ:NLNK) last announced its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.21. The business had revenue of $10.37 million for the quarter, compared to analysts’ expectations of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. Analysts anticipate that NewLink Genetics Corporation will post ($2.73) EPS for the current year.
In related news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of NewLink Genetics Corporation stock in a transaction dated Friday, October 6th. The shares were acquired at an average cost of $10.25 per share, for a total transaction of $7,999,991.75. Following the completion of the purchase, the insider now owns 7,857,732 shares in the company, valued at $80,541,753. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 13.70% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect NewLink Genetics Corporation (NASDAQ:NLNK) Share Price” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/28/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-newlink-genetics-corporation-nlnk-share-price.html.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.